var data={"title":"Cyclosporine (ciclosporin) (ophthalmic): Pediatric drug information \t","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Cyclosporine (ciclosporin) (ophthalmic): Pediatric drug information \t</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/41422?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=cyclosporine-ciclosporin-ophthalmic-drug-information\" class=\"drug drug_general\">see &quot;Cyclosporine (ciclosporin) (ophthalmic): Drug information \t&quot;</a> and <a href=\"topic.htm?path=cyclosporine-ciclosporin-ophthalmic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Cyclosporine (ciclosporin) (ophthalmic): Patient drug information \t&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8012533\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Restasis;</li>\n      <li>Restasis Multidose</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14959798\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Restasis</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10825664\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Immunosuppressant Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10825670\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=cyclosporine-ciclosporin-ophthalmic-drug-information\" class=\"drug drug_general\">see &quot;Cyclosporine (ciclosporin) (ophthalmic): Drug information \t&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Keratoconjunctivitis sicca:</b> Adolescents &ge;16 years: Ophthalmic: Instill 1 drop in each eye every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Vernal  keratoconjunctivitis (VKC), severe:</b> Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Treatment: Children and Adolescents  5 to 14 years: Ophthalmic: Instill 1 drop (0.05%)  in affected eye(s) 4 times daily. Dosing based on experience from a prospective trial of 54 pediatric patients (mean age: 9.6 years; range: 5 to 14 years); after 3 months of therapy, improved symptoms were observed, no adverse effects were reported (Keklikci 2008).  A case series in six patients (6 to 14 years) treated with 1 drop twice daily or 4 times daily was also shown to improve symptoms; in four patients cyclosporine was weaned after 6 months (n=1) or 12 months (n=3) of therapy; in three other patients, therapy was still ongoing at the time of publication  (Ozcan 2007). Higher concentrations of cyclosporine have also shown efficacy in clinical trials (1% and 2%); however, those formulations have a different vehicle and are not commercially available in the US (Vichyanond 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Prevention: Children &ge;6 years and Adolescents: Ophthalmic:  Instill 1 drop (0.05%) in affected eye(s) twice daily; dosing  based on a blinded, comparative (ketotifen) crossover trial in 34 pediatric patients (mean age: 14 &plusmn; 7 years) with severe but stable VKC; over a 2-year period, cyclosporine showed a statistically significant reduction in number of recurrences or flare-up compared to ketotifen; both drugs were considered to be well-tolerated (Lambiase 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Keratoconjunctivitis sicca:</b> Ophthalmic: Instill 1 drop in each eye every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b>   There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment unlikely necessary due to low systemic absorption.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b>   There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment unlikely necessary due to low systemic absorption.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8012680\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Emulsion, Ophthalmic [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Restasis: 0.05% (1 ea) [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Restasis Multidose: 0.05% (5.5 mL) [contains cremophor el, polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8012548\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10825671\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Prior to use, invert vial several times to obtain a uniform emulsion. Prime multidose bottle for first-time use by squeezing 2 drips onto a tissue; do not let bottle tip touch tissue. Avoid contact of vial tip with skin or eye; remove contact lenses prior to administration; lenses may be inserted 15 minutes after instillation. May be used with artificial tears; separate administration by at least 15 minutes.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49130961\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 2]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends double gloving, a protective gown, and (if liquid that could splash) eye/face protection for administration of a topical product (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8012598\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Store at 15&deg;C to 25&deg;C (59&deg;F to 77&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10825665\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Increase tear production in patients with moderate to severe keratoconjunctivitis sicca-associated ocular inflammation (FDA approved in ages &ge;16 years and adults); has also been used for the treatment and prevention of vernal keratoconjunctivitis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8012532\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">CycloSPORINE may be confused with cyclophosphamide, Cyklokapron, cycloSERINE</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Restasis may be confused with Refresh Celluvisc</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8012586\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Foreign body sensation of eye</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Blurred vision, burning sensation of eyes, conjunctival hyperemia, epiphora, eye discharge, eye pain, eye pruritus, stinging of eyes, visual disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Eye injury (from bottle tip during administration), hypersensitivity reaction (including angioedema, dyspnea, facial swelling, pharyngeal edema, swelling of eye, swollen tongue, urticaria)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8012551\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to cyclosporine or any component of the formulation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8012562\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Contact lens wearers: Remove contact lens prior to administration and wait 15 minutes before reinserting.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: To avoid contamination, do not touch vial tip to eyelids or other surfaces.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299110\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8012590\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=15961&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10923624\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed following the use of oral cyclosporine in animal reproduction studies. Serum concentrations are below the limit of detection (&lt;0.1 ng/mL) following ophthalmic use; fetal exposure following ophthalmic administration is not expected.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8012626\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">Absorption: Serum concentrations were below the quantitation limit of 0.1 ng/mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8012682\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Emulsion</b> (Restasis Multidose Ophthalmic)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.05% (5.5 mL): $611.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Emulsion</b> (Restasis Ophthalmic)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.05% (1): $10.19</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10961967\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Clacier (KR);</li>\n      <li>Cyclomune (IN);</li>\n      <li>Cyporin (BD, LK);</li>\n      <li>Ikervis (ES, GB);</li>\n      <li>Modusik-A Ofteno (CN, PE);</li>\n      <li>Papilock (JP);</li>\n      <li>Restasis (AR, BB, BR, CN, CO, GR, HK, IL, KR, LB, MY, PE, PH, SI, TH, TW, UA, VE, VN);</li>\n      <li>Restor (BD);</li>\n      <li>Sporium (BD)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Keklikci U, Soker SI, Sakalar YB, Unlu K, Ozekinci S, Tunik S. Efficacy of topical cyclosporin A 0.05% in conjunctival impression cytology specimens and clinical findings of severe vernal keratoconjunctivitis in children. <i>Jpn J Ophthalmol</i>. 2008;52(5):357-362.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-ophthalmic-pediatric-drug-information/abstract-text/18991035/pubmed\" target=\"_blank\" id=\"18991035\">18991035</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lambiase A, Leonardi A, Sacchetti M, Deligianni V, Sposato S, Bonini S. Topical cyclosporine prevents seasonal recurrences of vernal keratoconjunctivitis in a randomized, double-masked, controlled 2-year study. <i>J Allergy Clin Immunol</i>. 2011;128(4):896-897.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-ophthalmic-pediatric-drug-information/abstract-text/21868078/pubmed\" target=\"_blank\" id=\"21868078\">21868078</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ozcan AA, Ersoz TR, Dulger E. Management of severe allergic conjunctivitis with topical cyclosporin a 0.05% eyedrops. <i>Cornea</i>. 2007;26(9):1035-1038.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-ophthalmic-pediatric-drug-information/abstract-text/17893529/pubmed\" target=\"_blank\" id=\"17893529\">17893529</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Restasis (cyclosporine ophthalmic) [prescribing information]. Irvine, CA: Allergan, Inc; December 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Restasis Multidose (cyclosporine) [prescribing information]. Irvine, CA: Allergan Inc; October 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vichyanond P, Kosrirukvongs P. Use of cyclosporine A and tacrolimus in treatment of vernal keratoconjunctivitis.<i> Curr Allergy Asthma Rep</i>. 2013;13(3):308-314.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cyclosporine-ciclosporin-ophthalmic-pediatric-drug-information/abstract-text/23625179/pubmed\" target=\"_blank\" id=\"23625179\">23625179</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 15961 Version 78.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F8012533\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F14959798\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F10825664\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F10825670\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F8012680\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F8012548\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F10825671\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49130961\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F8012598\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F10825665\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F8012532\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F8012586\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F8012551\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F8012562\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299110\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F8012590\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F10923624\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F8012626\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F8012682\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F10961967\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/15961|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=cyclosporine-ciclosporin-ophthalmic-drug-information\" class=\"drug drug_general\">Cyclosporine (ciclosporin) (ophthalmic): Drug information \t</a></li><li><a href=\"topic.htm?path=cyclosporine-ciclosporin-ophthalmic-patient-drug-information\" class=\"drug drug_patient\">Cyclosporine (ciclosporin) (ophthalmic): Patient drug information \t</a></li></ul></div></div>","javascript":null}